58
Participants
Start Date
August 31, 2004
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Bortezomib
Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
CC-5013
Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
St. Vincent's Comprehensive Cancer Center, New York
Winship Cancer Center, Atlanta
H. Lee Moffitt Cancer Center, Tampa
University of Michigan, Ann Arbor
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Center, Boston
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Dana-Farber Cancer Institute
OTHER